SITE MAP   |   CONTACT US



Biovail Corporation is regularly covered by a number of analysts, including those listed here.

Firm Analyst Phone
Bank of America Merrill Lynch GreggGilbert (646) 855-1004
BMO Capital Markets Corp RobertHazlett (212) 885-4091
Canaccord Genuity NeilMaruoka (416) 869-3073
CRT Capital Group LLC TimChiang (203) 569-4355
Deutsche Bank DavidSteinberg (415) 617-3296
GMP Securities Ltd. CosmeOrdonez (514) 288-9279
Goldman Sachs & Company Inc. RandallS. Stanicky (212) 357-3292
J.P. Morgan ChrisSchott (212) 622-5676
Lazard Capital Markets WilliamTanner (212) 632-1512
National Bank Financial HariSambasivam (416) 869-7801
Paradigm Capital AlanRidgeway (416) 361-9080
Piper Jaffray & Co DavidAmsellem (212) 284-9455
RBC Capital Markets DougMiehm (416) 842-7823
Stifel, Nicolaus & Company, Inc. AnnabelSamimy (212) 271-3823
TD Securities LennoxGibbs (416) 308-2213
UBS MarcGoodman (212) 713-1342

Tools

Investment Calculator


Email Alerts

Resources

Q2 2010 Financial Results

Valeant - Biovail Analyst Investor Presentation

Biovail - Valeant Merger Conference Call

Biovail's Product Pipeline

Pimavanserin Schizophrenia Co-Therapy - Phase 2 Data

Aplenzin Prescribing Information

Nitoman Prescribing Information

Xenazine Prescribing Information

Xenazine Medication Guide

Corporate Fact Sheet

IMPORTANT: Income Tax Information for Canadian Resident Shareholders


Download Adobe Acrobat Reader

Events




© 2007 Biovail Corporation - All Rights Reserved (BIO113B0602) Privacy Policy   |   Disclaimers